GlassScriptPhysician profile
Angela Hackett Wortham
NPI 1396941449
$713.53
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $65.14 · 2022: $443.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viewray Technologies INC | $375.84 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $77.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $51.60 | 2019-2020 | |
| Janssen Biotech, INC. | $47.90 | 2022 | |
| Clovis Oncology, INC. | $34.37 | 2019-2020 | |
| Puma Biotechnology, INC. | $31.90 | 2019 | |
| Seagen INC. | $22.78 | 2019 | |
| Myriad Genetic Laboratories, INC. | $19.05 | 2022 | |
| Merck Sharp & Dohme LLC | $16.38 | 2020 | |
| Amgen INC. | $13.41 | 2019 | |
| Lilly USA, LLC | $11.29 | 2019 | |
| Coherus Oncology, INC. | $11.16 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Wortham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.